What is Nura Bio?
Nura Bio operates at the intersection of cutting-edge neuroscience and drug discovery. As a clinical-stage entity, the company focuses on the development of small molecule therapies that target the fundamental mechanisms of neurodegeneration. By prioritizing the preservation of axonal integrity and the regulation of microglial activity, Nura Bio is carving out a specialized niche in the biopharmaceutical sector. Its research-driven approach aims to provide transformative treatments for a broad spectrum of neurological disorders, positioning the company as a pivotal player in the future of neuroprotection and regenerative medicine.
How much funding has Nura Bio raised?
Nura Bio has raised a total of $213.8M across 2 funding rounds:
Series A
$140M
Series B
$73.8M
Series A (2024): $140M with participation from Samsara BioCapital, Sanofi Ventures, and The Column Group
Series B (2026): $73.8M led by The Column Group, Sanofi Ventures, and Samsara BioCapital
Key Investors in Nura Bio
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model that supports companies from inception to exit.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative potential in core therapeutic areas.
Samsara BioCapital
Samsara BioCapital partners with scientists and drug developers to create transformative therapeutics, leveraging deep industry experience to drive innovation in the biopharmaceutical sector.
What's next for Nura Bio?
With the successful closure of this latest financing, Nura Bio is well-positioned to advance its lead candidates through critical clinical milestones. The strategic allocation of these funds will likely prioritize the expansion of its R&D infrastructure and the acceleration of its clinical trial programs. As the company transitions into more advanced stages of development, the focus will shift toward validating its neuroprotective platform in human subjects, potentially setting the stage for future partnerships or commercialization efforts. The continued support from its core investor syndicate provides the necessary runway to navigate the high-stakes environment of drug development and bring life-altering therapies to patients suffering from chronic neurological decline.
See full Nura Bio company page
